ArticleOncotarget2018

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

Viktor Arnhold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.